MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on May 9, 2007; DOI: 10.1124/mol.107.034637


0026-895X/07/7202-311-319$20.00
Mol Pharmacol 72:311-319, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.034637v1
72/2/311    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lansiaux, A.
Right arrow Articles by Pierré, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lansiaux, A.
Right arrow Articles by Pierré, A.

Novel Stable Camptothecin Derivatives Replacing the E-Ring Lactone by a Ketone Function Are Potent Inhibitors of Topoisomerase I and Promising Antitumor Drugs

Amélie Lansiaux, Stéphane Léonce, Laurence Kraus-Berthier, Christine Bal-Mahieu, Romain Mazinghien, Sébastien Didier, Marie-Hélène David-Cordonnier, Patrick Hautefaye, Gilbert Lavielle, Christian Bailly1, John A. Hickman, and Alain Pierré

Institut National de la Santé et de la Recherche Médicale U837, Université de Lille 2, Facultéde Médecine, Institut de Médecine Prédictive et Recherche Thérapeutique, Centre Oscar Lambret and Institut de Recherches sur le Cancer de Lille, Lille, France (A.L., C.B.-M., R.M., S.D., M.-H.D.-C., C.B.); and Division of Cancer Drug Discovery, Institut de Recherches Servier, Croissy sur Seine, France (S.L., L.K.-B., P.H., G.L., J.A.H., A.P.)

The E-ring lactone is the Achilles' heel of camptothecin derivatives: although it is considered necessary for the inhibition of the enzyme topoisomerase I (topo1), the opening of the lactone into a carboxylate abolishes the generation of topo1-mediated DNA breaks. S38809 is a novel camptothecin analog with a stable 5-membered E-ring ketone; therefore, it lacks the lactone function. DNA relaxation and cleavage assays revealed that S38809 functions as a typical topo1 poison by stimulating DNA cleavage at T{downarrow}G sites. The activity was strongly dependent on the stereochemistry of the C-7 carbon atom that bears the hydroxy group. S38809 proved to be a potent cytotoxic agent, with a mean IC50 of 5.4 nM versus 11.6 nM for topotecan and 3.3 nM for SN38 (the active metabolite of irinotecan) on a panel of 31 human tumor cell lines. The cytotoxicity of S38809 and its ability to stabilize cleavable complexes was considerably reduced in camptothecin-resistant cells that express a mutated topo1, confirming that topo1 is its primary target. Cell death induced by topo1 poisoning requires the conversion of DNA single-strand breaks into double-strand breaks that can be detected by the formation of phosphorylated histone H2AX. In HCT116 cells, topotecan, SN38, and S38809 induced histone H2AX phosphorylation in S phase of the cell cycle, with S38809 being as potent as SN38 and 5-fold more potent than topotecan. In vivo, S38809 showed a marked antitumor activity against HCT116 xenografts. These findings open a new route for improving the pharmacological properties of camptothecin derivatives.


Received February 5, 2007; accepted May 9, 2007

Address correspondence to: Dr. Amélie Lansiaux, INSERM U-837 and Centre Oscar Lambret, ICRL, 59045 Lille, France. E-mail: amelie.lansiaux{at}lille.inserm.fr







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics